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Abstract: Corticotropin-releasing factor (CRF) is a peptide involved in the activation of the hypothalamic-pituitary-adrenal 
(HPA) axis. CRF is distributed not only along the HPA axis but also throughout pain-relevant anatomical sites. CRF elicits 
potent antinociception at the three main levels of pain transmissions: namely, the brain, spinal cord, and peripheral sensory 
neurons. The widespread distribution of CRF receptors 1 and 2 in the brain offers several targets wherein CRF could alter pain, 
some of which may be independent of the HPA axis. In this study, we assessed the expression of CRF and its receptors, CRF 
receptor type (CRFR)1 and CRFR2, in the spinal dorsal horn and dorsal root ganglion (DRG) in a rat model of neuropathic 
pain induced by spinal nerve injury (SNI). CRF was expressed in a few DRG neurons and primary afferent fibers in the dorsal 
horns of naїve rats, and the CRF-positive neurons in DRG and fibers in the spinal dorsal horn were found to have increased 
after SNI. CRFR1 was not expressed in DRG or the dorsal horn and CRFR2 was expressed weakly in the small neurons in DRG 
in the naїve rats. After SNI, CRFR1 was expressed in the activated microglia in the ipsilateral dorsal horn, and immunoreaction 
for CRFR2 was increased in the contralateral DRG following SNI. Consequently, it has been suggested that the increased 
expression of CRF and CRFR2 in DRG neurons and primary afferent fibers in dorsal horn, and CRFR1 in the activated 
microglia, may be involved in the mediation of stress responses as well as in microglial activation in the neuropathic pain state 
following SNI. 
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adrenal (HPA) axis; CRF also performs a pivotal role in the 
body’s responses to stress. The CRF family is composed of 
CRF and the CRF ligands mammalian, urocortin (Ucn) 1, 
and Ucn 2. The CRF receptor (CRFR) subtypes, CRFR1 and 
R2, evidence different affinity for CRF, Ucn1, Ucn 2, and Ucn 
3 [1, 2].
CRF not only stimulates the pituitary adrenal axis but also 
influences a variety of central nervous system (CNS) functions 
[3]. CRF-positive neurons are located primarily within the 
paraventriculo-infundibular system and are also found in 
Introduction 
Corticotropin-releasing factor (CRF) is a peptide known 
to be involved in the activation of the hypothalamic-pituitary-Expression of CRF in primary afferents
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many areas of the CNS associated with the stress response, 
such as the amygdala and nucleus accumbens [4, 5]. CRF also 
functions as a neurotransmitter or neuromodulator in the 
sensory system. CRF-positive cells and fibers have previously 
been detected in the dorsal root ganglion (DRG) [6], lateral 
column, lamina I, V-VII, X, and in the intermediolateral 
column. The majority of CRF-positive fibers in spinal cords 
were believed to be ascending fibers, as they did not disappear 
after spinal cord transection [5]. The distribution of the CRF-
immunoreactive fibers in the lumbosacral cord is similar to 
that of the pelvic nerve afferents; this raises the possibility 
that CRF may function as a transmitter in afferent neurons 
innvervating the pelvic viscera [7]. The receptors of CRF 
are known to be distributed broadly throughout the CNS, 
including in the spinal cord, as demonstrated by the results of 
earlier autoradiographic studies [8], In the spinal cord, CRFRs 
are highly concentrated in the superficial laminae [9] and also 
in lamina VII and lamina X. 
The CRF is known to exert an antinociceptive effect, 
which is mediated by CRFRs in the HPA axis, the amygdala, 
and the spinal cord [9, 10]. The functional relation of CRF 
with pain is based on its expression in the anatomical sites 
of pain transmission as well as the HPA axis [11]. The local 
injection of CRF in the brain, spinal cord, and periphery 
has been shown to produce antinociceptive effects against 
inflammatory pain, and this action may be mediated by 
CRFRs in opiod-expressing interneurons [12]. The activation 
of endogenous CRFR1 in the amygdala also contributes to 
pain-related synaptic facilitation, increased excitability, and 
pain behavior [13, 14]. In previous immunohistochemical 
studies, CRFRs have been detected primarily in the areas of 
the spinal cord associated with visceral sensation [15-17]; 
however, the changes in CRF expression associated with the 
neuropathic pain state have yet to be clearly elucidated. 
It has been suggested in recent studies that the 
immunological activity of the CRF is relevant to the 
peripheral antinociceptive effects of CRF [18], and also that 
CRF may regulate neuroinflammation by inducing microglial 
apoptosis [19]. Microglial activation after spinal nerve injury 
(SNI) is a major factor in the development of neuropathic 
pain [20].  
We hypothesized that the expression of CRF and its 
receptors in the spinal cord and DRG neurons are altered in 
the neuropathic pain state, and that they may contribute to 
microglial activation. In this study, we evaluated changes in 
the expressions of CRF and its receptors CRFR1 and CRFR2 
in the spinal cord and DRG in a rat model of peripheral nerve 
injury-induced neuropathic pain.
Materials and Methods
Animals 
Twenty-five male Sprague-Dawley rats weighing 160-180 
g each were used in this study. The rats were housed three per 
cage, and were provided with free access to water and food. 
All animal experiments were approved by the Institutional 
Animal Care and Use Committee of Hanyang University. 
Rat model for neuropathic pain induced by SNI
Neuropathic pain was induced via a modification of the 
spinal nerve ligation model [21]. The experimental animals 
were subdivided into naїve (5 rats), sham control (10 rats) 
and SNI groups (10 rats). The rats were anesthetized using a 
mixture of Zoletil (27.78 mg/kg, i.p.) and Xylazine (0.647 mg/
kg, i.p.). The left transverse process of the L6 vertebra was 
removed through an incision on the skin of the back, and the 
L5 and L6 spinal nerves of the left side were transected and 
1 mm segments of their distal ends were cut [22]. The sham 
control group operation was also conducted via the same 
procedure as mentioned above, with the exception of L5 and 
L6 SNI.
Behavioral test for mechanical hyperalgesia
Neuropathic pain was evaluated by measuring the 
threshold of 50% paw withdrawal responses to mechanical 
stimulation. The rats were assessed for mechanical allodynia 
of the plantar surface of the hindpaw of the left side 2 days 
prior to surgery, and 1, 2, 4, 7, and 14 days after surgery by 
von Frey filaments. The rats were placed on the metal mesh 
floor under custom-made transparent acrylic cells without a 
floor and accommodated for 15 minutes. In an effort to assess 
mechanical allodynia, von Frey filaments (0.25, 0.65, 1.05, 
1.56, 2.60, 4.89, 6.16, 8.40, 15.25, and 21.75 g) were pressed 
onto the plantar surface via an up-and-down paradigm 
beginning with the 6.16 g filament, and the 50% paw 
withdrawal response threshold was calculated as previously 
described [23]. 
 Statistical analyses were conducted via one-way ANOVA 
using the SPSS ver. 12.0 (SPSS Inc., Chicago, IL, USA). The 
threshold for statistical significance was set at P<0.005.  Anat Cell Biol 2011;44:60-68 Eun Hyun Kim, et al 62
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Immunohistochemistry
 The animals were perfused with 4% paraformaldehyde 
in phosphate buffer (PB, 0.1M, pH 7.4) at 7 and 14 days after 
surgery. The L5 DRG and spinal cord were fixed for 4 hours 
in the same solution and cryoprotected overnight in 30% 
sucrose in PB. Transverse sections of the L5 spinal cord (30 
μm) and DRG (20 μm) were cut on a cryostat, blocked with 
10% normal donkey serum (NDS; Jackson ImmunoResearch 
Laboratories, West Grove, PA, USA) in phosphate-buffered 
saline (PBS; 0.01M, pH 7.2) for 40 minutes, and incubated 
overnight with primary antibodies. For immunofluorescence, 
the sections were incubated with a mixture of the primary 
antibodies. The primary antibodies used were rabbit anti-
CRF (1 : 1,000, Phoenix, Burlingame, CA, USA), goat anti-
transient receptor potential vanilloid 1 receptor (TRPV1; 1 
: 500, Neuromics, Edina, MN, USA), goat anti-CRFR1 (1 : 
100, Santa Cruz, Santa Cruz, CA, USA), goat anti-CRFR2 
(1 : 100, Santa Cruz) and rabbit anti-Iba1 (1 : 1,000, Wako, 
Fig. 1. Von Frey test for the assessment of mechanical hyperalgesia in 
the sham control (sham) and spinal nerve injury (SNI) rats. The SNI 
rats evidenced reductions in the paw withdrawal threshold relative to 
the sham control group. One-way ANOVA (n=5, *P<0.005 vs. Con, 
#P<0.005 vs. sham).
Fig. 2. Corticotropin-releasing factor (CRF) and transient receptor potential vanilloid 1 receptor (TRPV1) expression in the L5 dorsal root 
ganglion (DRG) of the naїve and spinal nerve injury (SNI) rats. (A) In the DRG of naїve rats, CRF was expressed in a few small neurons, and the 
majority of CRF-positive neurons also expressed TRPV1 (arrows). (B) After SNI, virtually all immunoreactivity for CRF and TRPV1 disappeared 
in the ipsilateral (ipsi) DRG. (C) In the contralateral (contra) DRG of the SNI group rats, the levels of CRF-positive neurons were increased 
relative to that of naїve rats. (D) The number of CRF-positive neurons in ipsilateral and contralateral DRGs in naїve rats and SNI group rats. One-
way ANOVA (n=5, *P<0.05 vs. naїve). Scale bar=20 μm.Expression of CRF in primary afferents
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Osaka, Japan). The following day, the sections were rinsed 
and incubated for 15 minutes in 2% NDS and then incubated 
for 3 hours with a mixture of the secondary antibodies, anti-
goat or anti-rabbit secondary antibodies conjugated to Cy3 
(1 : 200, Jackson ImmunoResearch Laboratories) or Alexa 
488 (1 : 200, Invitrogen, Carlsbad, CA, USA) in PBS. After 
washing, the sections were coverslipped with Vectashield 
(Vector Laboratories, Burlingame, CA, USA), and visualized 
on a Leica DMR microscope. Images were acquired with a 
CCD camera (Fluoview, SIS, Muenster, Germany) attached 
to the microscope or a confocal microscope (SP-5, Leica, 
Heidelberg, Germany). 
 To quantify the number of CRF-positive neurons in DRG, 
15 DRG sections from 5 animals in each group were selected 
and the numbers of CRF-positive neurons were counted. To 
assess CRFR1 intensity in the spinal dorsal horn and CRFR2 
intensity in the DRG, 15 spinal cord sections and DRG 
sections from 5 animals in each group were selected and 
the representative intensity was determined and expressed 
as follows: + (weak intensity), ++ (moderate intensity), +++ 
(strong intensity).          
Table 1. The intensity of CRF immunoreactivity in the contralateral and 
ipsilateral dorsal horns of the naїve rats and the rats 7 days (SNI 7d) and 14 
days after SNI (SNI 14d)
Naїve SNI 7d SNI 14d
Contralateral  + ++ ++
Ipsilateral  + + +
Values were expressed as representative intensities out of 15 sections from 5 rats 
in each group. +, weak intensity; ++, moderate intensity; +++, strong intensity. 
CRF, corticotropin-releasing factor; SNI, spinal nerve injury.
Fig. 3. Corticotropin-releasing factor (CRF) expression in the spinal dorsal horn in the naїve and spinal nerve injury (SNI) group rats. (A) 
In the spinal cords of naїve rats, CRF-immunoreactive fibers and puncta were noted in the superficial laminae of the dorsal horn. (B, C) CRF 
immunoreactive fibers and puncta were increased in lamina I, II of the contralateral (contra) dorsal horn after SNI. Ipsi, ipsilateral. Scale bars=500 
μm (left column), 200 μm (middle column).Anat Cell Biol 2011;44:60-68 Eun Hyun Kim, et al 64
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Results 
 
Pain behavior after SNI 
Mechanical hyperalgesia after SNI was evaluated via von 
Frey tests. In the SNI group, mechanical withdrawal threshold 
in the ipsilateral (left side) hindpaw was reduced significantly 
at 1 day after surgery compared to the control and sham 
animals, and the reduced levels were sustained until 14 days. 
In the sham group, the threshold was reduced at 1 day after 
surgery and recovered 2 days after surgery (Fig. 1).   
CRF expression in the spinal dorsal horn and DRG
Immunohistochemical CRF expression was assessed 
in the DRG and the spinal cord at the L5 level. TRPV1 
immunohistochemistry was also carried out in the DRG to 
characterize the CRF positivity of the DRG neurons. In the 
DRG of naїve animals, strong immunoreactivity for CRF was 
noted in a few small cells; these cells were also stained for 
TRPV1. In ipsilateral DRG at the L5 level 7 and 14 days after 
SNI, virtually all CRF immunoreactivity disappeared. In the 
contralateral DRG of the SNI group, CRF-positive neurons 
were increased relative to the naїve and sham control groups 
(Fig. 2). 
In the spinal cords of naїve rats, CRF immunoreactivity 
was observed in the fibers and puncta in lamina I-II of the 
dorsal horn. At 7 and 14 days after SNI, CRF-positive fibers 
were increased in the contralateral dorsal horn relative to 
the naїve and sham control animals. 14 days after SNI, the 
CRF-positive fibers were also increased in the lamina I of the 
ipsilateral dorsal horn relative to that observed 7 days after 
SNI (Table 1, Fig. 3).  
CRFR1 and R2 expression in the spinal dorsal horn 
and DRG 
In the spinal cords of the naїve and sham control rats, no 
clearly CRFR1-positive cells were s observed in the spinal 
cord and DRG. Seven and 14 days after SNI, CRFR1-positive 
cells were observed in the deeper laminae of the dorsal 
horn. In the double-labeling staining with Iba1, a marker for 
microglia, those CRFR1-positive cells were co-stained with 
Iba1; the results confirmed that CRFR1-positive cells in the 
deeper laminae were activated microglia (Fig. 4).
Very weak immunoreactivity for CRFR2 was detected 
in the spinal cord and DRG of the naїve and sham control 
animals. The intensity and number of CRFR2-immunoreactive 
cells were increased in the contralateral DRG of the SNI 
group. The sizes of the CRFR2-positive cells varied from 
small-sized to medium- and large-sized cells (Table 2, Fig. 5). 
Discussion 
In this study, we evaluated the expression of CRF and its 
receptors in the spinal cord and DRG; the main results are 
as follows: 1) CRF was normally expressed in the superficial 
laminae of the dorsal horn and a few small neurons in 
DRG; 2) After SNI, CRF-immunoreactive neurons in DRG 
and primary afferent fibers in the spinal dorsal horn were 
increased on the contralateral side of the injury; 3) CRFR1- 
and CRFR2-positive cells were not observed in the normal 
spinal cord and DRG; 4) After SNI, CRFR1 receptors are 
expressed in the microglia in the deeper lamina of the dorsal 
horn and CRFR2 receptors were expressed in the contralateral 
DRG.        
The existence of the CRF in DRG and primary afferent 
fibers in spinal dorsal horns has been demonstrated in 
previous studies, but the role played by CRF in the pain 
transmission pathway to antinociception was not defined, 
because the CRF was shown to exert antinociceptive effects 
mainly on higher centers, including the HPA axis. Most 
studies regarding the action of CRF in the spinal cord have 
focused on visceral sensations. Recently, it was determined 
in electrophysiological experiments that CRF can modulate 
sensory transmission by modulating the activity of the spinal 
neurons [24]. To the best of our knowledge, there have been 
no reports regarding altered CRF expression in DRG neurons 
subsequent to peripheral nerve injury. We determined that 
CRF expression is upregulated in both DRG neurons and 
primary afferent fibers in the contralateral dorsal horn after 
SNI. The upregulation of CRF in DRG neurons after SNI may 
be a response to stress on the peripheral and spinal levels, and 
may also perform a relevant function in the modulation of 
pain transmission at the spinal level. However, CRF-positive 
cells in the DRG ipsilateral to injury were not observed. In 
our nerve injury model, all peripheral axons of the L5 nerve 
were cut. The axotomized DRG neuron on the ipsilateral 
side, and particularly small-sized cells, are known to be 
susceptible to degenerative and apoptic changes resulting 
from starvation of neurotrophic factors, prolonged expression 
of c-Jun transcription factors, and low levels of the cell death 
repressors Bcl-2 and Bcl-XL [25, 26]. Local upregulation of 
CRF may occur in the DRG neurons of the contralateral side, Expression of CRF in primary afferents
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but not in the neurons of the ipsilateral side whose axons have 
been damaged by SNI.  
CRFR1 was expressed in the deeper laminae of the dorsal 
horn and CRFR2 in contralateral DRG neurons after SNI. 
CRFR1 and R2 evidence widespread distribution in the CNS 
and other peripheral organs. CRFR1 is expressed in the brain, 
pituitary gland, gonads, and skin, and CRFR2 is expressed 
in the brain and the cardiac and skeletal muscles [2]. In the 
Fig. 4. Corticotropin-releasing factor receptor type 1 (CRFR1) expression in the Iba1-positive microglia in the spinal dorsal horn. (A) 
Immunoreactivity for CRFR1 was not noted in the dorsal horn of the naїve animals. (B) Immoreactivity for CRFR1 was noted in the activated 
microglia in the laminae III-V, but not in the lamina I-II (asterisk), of the ipsilateral (ipsi) dorsal horn at 7 days after spinal nerve injury (SNI). 
(C) At 14 days after SNI, CRF expression was weaker relative to that observed 7 days after SNI. (D) Confocal microscopy for CRFR1 and Iba1 
expression in the ipsilateral dorsal horn at 14 days after SNI. CRFR1-positive cells in the ipsilateral dorsal horn were also stained for Iba1 (arrows) 
in the deeper laminae. Contra, contralateral. Scale bars=500 μm (A-C), 50 μm (D).Anat Cell Biol 2011;44:60-68 Eun Hyun Kim, et al 66
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spinal cord, the expression of CRFRs has been detected in 
neurons in lamina VII and X [16], in cultured microglia, and 
in activated microglia in paraventricular nucleus [27], as well 
as in the brain following ischemic damage [28]; however, 
no expression in the spinal microglia after SNI has yet been 
reported. 
 Microglial activation is a key factor in defense mechanisms 
exploited in response to neuronal injuries such as infection, 
inflammation, and ischemia [29], but activated microglia 
are also known to play an active role in the development 
and maintenance of the neuropathic pain state [20, 30, 31]. 
Accordingly, the inhibition or attenuation of microglial 
activation has been considered recently as a possible new tool 
for the treatment of neuropathic pain induced by spinal nerve 
or spinal cord injury [32, 33]. Interestingly, a previous report 
asserted that CRF may regulate neuroinflammation via the 
induction of microglial apoptosis under in vitro conditions 
[19]. Upregulated CRF in the DRG neurons has been 
suggested to act on microglial CRFR1 to modulate microglial 
activation and neuropathic pain. CRFR2 expression in the 
DRG neurons was also unexpected. In future studies, the 
Table 2. The intensity of immunoreactivity for CRFR2 in contralateral and 
ipsilateral DRG of the naїve rats and rats at 7 (SNI 7d) and 14 days (SNI 14d) 
after SNI
Naїve SNI 7d SNI 14d
Contralateral  + +++ +++
Ipsilateral  + +
The values were expressed as representative intensities out of 15 sections from 5 
rats in each group. +, weak intensity; +++, strong intensity. CRFR2, 
corticotropin-releasing factor receptor type 2; DRG, dorsal root ganglion; SNI, 
spinal nerve injury.
Fig. 5. Expression of corticotropin-releasing factor receptor type 2 (CRFR2) in the L5 dorsal root ganglion (DRG) of the sham control and spinal 
nerve injury (SNI) group rats. (A, B) In the sham control rats, weak immunoreactivity for CRFR2 was noted in the majority of DRG neurons. (C, D) 
The increase in CRFR2 immunoreactivity was observed in the neurons (arrows) of the contralateral (contra) DRG after SNI. Ipsi, ipsilateral. Scale 
bar=200 μm.Expression of CRF in primary afferents
doi: 10.5115/acb.2011.44.1.60
Anat Cell Biol 2011;44:60-68 67
www.acbjournal.com
www.acbjournal.org
functional significance of this receptor in the neuropathic 
pain state should be elucidated in greater detail.    
In summary, the results of this study suggest that the 
upregulation of CRFR1 in the microglia occurs as a direct 
response to peripheral nerve injury and the increased 
expression of CRF and CRFR2 in DRG neurons, and also may 
be involved in the mediation of general stress responses in the 
neuropathic pain state.
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